Chinese biopharma stocks have lucrative potential, but realizing gains will involve some growing pains. EMERGING RECENT REGULATORY changes in China have led to an outpouring of enthusiasm from investors and biopharmaceutical companies looking to gain a foothold in one of the worlds major markets - a market that was, until recently, stymied by restrictions that barred pre-revenue biotech firms from listing on the Hong Kong stock exchange.
展开▼
